Brief: Palvella Therapeutics Provides Corporate Update And 2026 Outlook
09/01/2026 12:55
Jan 9 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS PROVIDES CORPORATE UPDATE AND 2026 OUTLOOK: ADVANCING A LATE CLINICAL-STAGE PIPELINE AND PLATFORM TO ADDRESS MULTIPLE SERIOUS, RARE SKIN DISEASES AND VASCULAR MALFORMATIONS WITH NO FDA-APPROVED THERAPIES PALVELLA THERAPEUTICS INC - NDA SUBMISSION PLANNED FOR SECOND HALF OF 2026 PALVELLA THERAPEUTICS INC - PHASE 3 SELVA STUDY RESULTS EXPECTED IN MARCH 2026 PALVELLA THERAPEUTICS INC - REQUESTED BREAKTHROUGH THERAPY DESIGNATION MEETING WITH FDA IN Q1 2026 PALVELLA THERAPEUTICS INC - PHASE 2 CLINICAL STUDIES FOR QTORIN™ TO START IN H2 2026 Source text: ID:nGNX2QwHlD Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs